Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

First Posted Date
2020-06-12
Last Posted Date
2024-10-15
Lead Sponsor
Seagen Inc.
Target Recruit Count
40
Registration Number
NCT04430738
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇯🇵

National Cancer Center Hospital, Chuo-ku, Other, Japan

and more 19 locations

FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

First Posted Date
2020-05-19
Last Posted Date
2021-04-13
Lead Sponsor
Blokhin's Russian Cancer Research Center
Target Recruit Count
538
Registration Number
NCT04393584
Locations
🇷🇺

Aleksei Kalinin, Moscow, Russian Federation

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

First Posted Date
2020-05-15
Last Posted Date
2024-10-18
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
328
Registration Number
NCT04390399
Locations
🇺🇸

Avera Cancer Institute, Sioux Falls, South Dakota, United States

🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

🇺🇸

Hoag memorial Presbyterian Hospital, Newport Beach, California, United States

and more 1 locations

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

First Posted Date
2020-05-01
Last Posted Date
2024-04-19
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
200
Registration Number
NCT04371224
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

First Posted Date
2020-04-24
Last Posted Date
2023-08-28
Lead Sponsor
University of Chicago
Target Recruit Count
54
Registration Number
NCT04361708
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

First Posted Date
2020-04-21
Last Posted Date
2021-02-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
35
Registration Number
NCT04354662
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

First Posted Date
2020-04-01
Last Posted Date
2024-07-18
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
49
Registration Number
NCT04329494
Locations
🇺🇸

Northwell Health Cancer Institute at Huntington, Greenlawn, New York, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

First Posted Date
2020-03-09
Last Posted Date
2023-11-08
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
7
Registration Number
NCT04299880
Locations
🇯🇵

Kyorin University Hospital, Tokyo, Japan

🇺🇸

Maine Center for Cancer Medicine, Scarborough, Maine, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

and more 4 locations

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

First Posted Date
2020-02-05
Last Posted Date
2024-03-08
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
5
Registration Number
NCT04251715
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

First Posted Date
2020-01-30
Last Posted Date
2024-11-05
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
314
Registration Number
NCT04248452
Locations
🇺🇸

Mercy Cancer Center-West Lakes, Clive, Iowa, United States

🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States

and more 448 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy